

Please replace the paragraph beginning at page 60, line 2, with the following rewritten paragraph:

**Example 25**

**Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-AEEA<sub>n</sub>-MPA)-NH<sub>2</sub>.2TFA (SEQ ID NO: 66)**

Please replace the paragraph beginning at page 61, line 3, with the following rewritten paragraph:

A peptide stability assay was performed. (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH<sub>2</sub>. 2TFA (SEQ ID NO: 67) was synthesized as described above and was identified MPA-K5. The non-modified counterpart peptide Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH<sub>2</sub> (SEQ ID NO: 12) was also synthesized as described above without the addition of 3-MPA and identified as K5.

**REMARKS**

Reconsideration is respectfully requested. This is in response to the Notice of Non-Compliant Amendment (37 CFR 1.121) dated March 25, 2002, for which a response is due on April 25, 2002. This response includes a clean version of the replacement paragraphs in the specification, and therefore, the amendment filed on February 26, 2002 is now compliant with rule 1.121.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "**Version with markings to show changes made.**"

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing docket no. 500862002200.

Respectfully submitted,

Dated: April 9, 2002

By: Michael R. Ward  
Michael R. Ward  
Registration No. 38,651

Morrison & Foerster LLP  
425 Market Street  
San Francisco, California 94105-2482  
Telephone: (415) 268-6237  
Facsimile: (415) 268-7522

**VERSION WITH MARKINGS TO SHOW CHANGES MADE**

**In the Specification:**

Paragraph beginning at line 31, page 2 has been amended as follows:

In particular, the present invention relates to the following modified kringle 5 peptides: NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH<sub>2</sub> (SEQ ID NO: 17); NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub> (SEQ ID NO: 18); Nac-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub> (SEQ ID NO: 19); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub> (SEQ ID NO: 20); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-NH<sub>2</sub> (SEQ ID: NO 21); NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(N $\epsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO: 22); (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 23); (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 24); NAc-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( N $\epsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO: 25); (MPA-AEEA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 26); (MPA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 27); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( N $\epsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO: 28); (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 29); (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 30); NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-( N $\epsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO: 31); (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub> (SEQ ID NO: 32); (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub> (SEQ ID NO: 33); NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( N $\epsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO: 34); (MPA-AEEA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 35); (MPA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub> (SEQ ID NO: 36); NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-( N $\epsilon$ -MPA)-NH<sub>2</sub> (SEQ ID NO: 37);

(MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub> (SEQ ID NO: 38);  
(MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub> (SEQ ID NO: 39);  
NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( N $\epsilon$ -AEEA-MPA)-NH<sub>2</sub> (SEQ ID NO: 40);  
NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( N $\epsilon$ -AEEA<sub>n</sub>-MPA)-NH<sub>2</sub> (SEQ ID NO: 41); and  
other modified kringle 5 peptides.

Paragraph beginning at line 1, page 40 has been amended as follows:

**-- Example 1**

**Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH<sub>2</sub>.3TFA (SEQ ID NO: 42) --**

Paragraph beginning at line 15, page 40 has been amended as follows:

**-- Example 2**

**Preparation of NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub>.3TFA (SEQ ID NO: 43) --**

Paragraph beginning at line 29, page 40 has been amended as follows:

**-- Example 3**

**Preparation of Nac-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub>.3TFA  
(SEQ ID NO: 44) --**

Paragraph beginning at line 14, page 41 has been amended as follows:

**-- Example 4**

**Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-  
Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-NH<sub>2</sub>.4TFA (SEQ ID NO: 45) --**

Paragraph beginning at line 2, page 42 has been amended as follows:

**-- Example 5**

**Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-NH<sub>2</sub>.2TFA  
(SEQ ID NO: 46) --**

Paragraph beginning at line 18, page 42 has been amended as follows:

**-- Example 6**

**Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-MPA)-NH<sub>2</sub>.2TFA (SEQ ID  
NO: 47) --**

Paragraph beginning at line 16, page 43 has been amended as follows:

**-- Example 7**

**Preparation of (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA (SEQ ID NO: 48)**  
--

Paragraph beginning at line 13, page 44 has been amended as follows:

**-- Example 8**

**Preparation of (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA (SEQ ID NO: 49) --**

Paragraph beginning at line 7, page 45 has been amended as follows:

**-- Example 9**

**Preparation of NAc-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( Nε-MPA)-  
NH<sub>2</sub>.2TFA (SEQ ID NO: 50) --**

Paragraph beginning at line 4, page 46 has been amended as follows:

**-- Example 10**

**Preparation of (MPA-AEEA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA (SEQ ID NO: 51) --**

Paragraph beginning at line 3, page 47 has been amended as follows:

**-- Example 11**

**Preparation of (MPA)-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA (SEQ ID NO: 52) --**

Paragraph beginning at line 1, page 48 has been amended as follows:

**-- Example 12**

**Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( Nε-MPA)-NH<sub>2</sub>.3TFA (SEQ ID NO: 53)--**

Paragraph beginning at line 4, page 49 has been amended as follows:

**-- Example 13**

**Preparation of (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.3TFA (SEQ ID NO: 54) --**

Paragraph beginning at line 7, page 50 has been amended as follows:

**-- Example 14**

**Preparation of (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Ala-Tyr-Thr-Thr-Asn-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.3TFA (SEQ ID NO: 55) --**

Paragraph beginning at line 6, page 51 has been amended as follows:

**-- Example 15**

**Preparation of NAc-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-Lys-( Nε-MPA)-NH<sub>2</sub>.TFA (SEQ ID NO: 56) --**

Paragraph beginning at line 4, page 52 has been amended as follows:

**-- Example 16**

**Preparation of (MPA-AEEA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub>.TFA (SEQ ID NO: 57) --**

Paragraph beginning at line 2, page 53 has been amended as follows:

**-- Example 17**

**Preparation of (MPA)-Arg-Asn-Pro-Asp-Gly-Asp-Val-Gly-Gly-Pro-Trp-NH<sub>2</sub>.TFA (SEQ ID NO: 58) --**

Paragraph beginning at line 1, page 54 has been amended as follows:

**-- Example 18**

**Preparation of NAc-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( Nε-MPA)-NH<sub>2</sub>.2TFA (SEQ ID NO: 59) --**

Paragraph beginning at line 30, page 54 has been amended as follows:

**-- Example 19**

**Preparation of (MPA-AEEA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA (SEQ ID NO: 60)--**

Paragraph beginning at line 26, page 55 has been amended as follows:

**-- Example 20**

**Preparation of (MPA)-Arg-Lys-Leu-Tyr-Asp-Tyr-NH<sub>2</sub>.2TFA (SEQ ID NO: 61) --**

Paragraph beginning at line 20, page 56 has been amended as follows:

**-- Example 21**

**Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-(Nε-MPA)-NH<sub>2</sub>.2TFA (SEQ ID NO: 62) --**

Paragraph beginning at line 17, page 57 has been amended as follows:

**-- Example 22**

**Preparation of (MPA-AEEA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub>.2TFA (SEQ ID NO: 63)--**

Paragraph beginning at line 13, page 58 has been amended as follows:

**-- Example 23**

**Preparation of (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-NH<sub>2</sub>.2TFA (SEQ ID NO: 64) --**

Paragraph beginning at line 7, page 59 has been amended as follows:

**-- Example 24**

**Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-(Nε-AEEA-MPA)-NH<sub>2</sub>.2TFA (SEQ ID NO: 65) --**



Paragraph beginning at line 2, page 60 has been amended as follows:

**-- Example 25**

**Preparation of NAc-Pro-Arg-Lys-Leu-Tyr-Asp-Tyr-Lys-( Nε-AEEA<sub>n</sub>-MPA)-NH<sub>2</sub>.2TFA  
(SEQ ID NO: 66) --**

Paragraph beginning at line 3, page 61 has been amended as follows:

A peptide stability assay was performed. (MPA)-Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH<sub>2</sub>. 2TFA (SEQ ID NO: 67) was synthesized as described above and was identified MPA-K5. The non-modified counterpart peptide Pro-Arg-Lys-Leu-Tyr-Asp-Lys-NH<sub>2</sub> (SEQ ID NO: 12) was also synthesized as described above without the addition of 3-MPA and identified as K5.